Budget impact of VK2735
2 evidence topics · 20 sources
Summary: price, planned access channels, and comparator prices
No price, average sales price, or wholesale acquisition cost has been announced for either formulation of VK2735, and no cost-effectiveness analysis or budget impact model of VK2735 has been published. In 2026 investor conference transcripts, Viking Therapeutics described the obesity market as “50% of the business now is in cash”, stated that it is in discussions with direct-to-consumer companies, and said of that channel that “it's not through PBM, so there's no rebate wall”. The company stated that it “would expect to have access” to the Medicare GLP-1 Bridge program. In its Form 10-Q for the third quarter of 2026, the company stated that there would be “a much larger obesity market with reimbursement from third-party payors”.
Prices of the approved incretin-based comparators, as published in 2025 and 2026:
- Semaglutide (Wegovy): wholesale acquisition cost of $1,349.02 for a 4-pen package of the 2.4 mg or the 7.2 mg injection and for a 30-tablet bottle of the 25 mg tablets, on the manufacturer's pricing page. The manufacturer announced a list price of $675 per month across Wegovy, Ozempic, and Rybelsus effective January 1, 2027, with no change to self-pay prices, and a price of $149 per month for the 1.5 mg starting dose of the tablets with savings offers.
- Tirzepatide (Zepbound): a self-pay price “starting at $299” for all doses in the KwikPen or the single-dose vial through LillyDirect.
- Orforglipron (Foundayo): self-pay price starting at $149 per month for the lowest dose; as little as $25 per month with the savings card for eligible commercially insured people; and $50 per month for eligible Medicare Part D individuals beginning as soon as July 1, 2026.
- The American Diabetes Association 2026 Standards of Care list the average wholesale price and the National Average Drug Acquisition Cost for a 30-day supply as $1,619 and $1,303 for liraglutide 3 mg daily, $1,619 and $1,302 for semaglutide 2.4 mg once weekly, and $1,304 and $1,022 for tirzepatide.
Summary: class-level budget impact and cost-effectiveness
In its final evidence report of December 2025, ICER modeled injectable semaglutide, oral semaglutide, and tirzepatide, each added to lifestyle modification, in a lifetime Markov cohort model from the health sector perspective with 3% annual discounting. At annual net prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide, with oral semaglutide assumed to cost the same as injectable semaglutide, the cost per QALY gained versus lifestyle modification was $57,779 for tirzepatide, $66,355 for injectable semaglutide, and $75,456 for oral semaglutide, and ICER estimated that no discount was needed to reach its health benefit price benchmarks. Over an undiscounted five-year horizon, ICER estimated about 92,000,000 eligible U.S. adults and a year-one budget impact per patient of $6,607 for injectable semaglutide and $7,711 for tirzepatide. Fewer than 1% of eligible people could be treated within five years without crossing ICER's $880 million annual threshold, including at the Medicare price of $245 per month.
Other U.S. analyses differ by price and perspective. ICER's prior assessment reported $237,000 per QALY gained for semaglutide at the net price then in effect. A peer-reviewed lifetime microsimulation reported $197,023 per QALY for tirzepatide and $467,676 per QALY for semaglutide, requiring discounts of 30.5% and 81.9% to reach $100,000 per QALY. A 30-year U.S. third-party payer model reported $23,556 to $144,296 per QALY gained for semaglutide 2.4 mg against its comparators, and a societal-perspective model estimated per-patient savings of $41,688 and 0.506 QALYs gained for tirzepatide versus semaglutide at maximum tolerated doses.
For Medicare, CBO estimated that authorizing coverage of anti-obesity medications would increase net federal spending by about $35 billion from 2026 to 2034, at a direct federal cost of roughly $5,600 per user in 2026. A published analysis estimated added annual Part D costs of $3.1 billion or $6.1 billion at 5% or 10% uptake among newly eligible patients. The CMS Medicare GLP-1 Bridge demonstration gives eligible Part D beneficiaries certain GLP-1 drugs for a $50 copay from July 1, 2026, to December 31, 2027, outside the Part D payment flow. In the KFF 2025 employer survey, 19% of firms with 200 or more workers covered GLP-1 agonists for weight loss. Obesity was associated with $1,861 in excess annual medical costs per adult (2019 dollars), and weight loss of 5% and 25% with estimated annual spending reductions of $670 and $2,849 among adults with employer-sponsored insurance.